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ABSTRACT 
Aim: The present study aimed to investigate the influence of histological factors on survival of patients with esophageal cancer. 
Background: Esophageal cancer is almost the common form of malignancy in the eastern world.  
Patients and methods: Through a retrospective cohort study a consecutive series of 134 patients with definite diagnosis 
of esophageal cancer who had been hospitalized at the Towhid hospital, Sanandaj city, Kurdistan province western Iran 
during a five-year period from 2006 onward were recruited. The survival time of patients stratified by this grouping 
method were analyzed by Kaplan-Meier analysis and Cox regression. 
Results: Overall, 127 males (55.1%), with a mean age of 65.38 ±11.62 years were included. Based on histological type 
of tumor, 23 patients (18.1%) had adenocarcinoma (AC) and 94 patients (74.0%) had squamous cell carcinoma (SCC). 
Gender was not significantly associated with survival (Log rank =0.480). Location of tumor (log rank=0.014), 
histological type (log rank ≤0.001) and grade of tumor (log rank =0.008) had significantly influenced the survival rates 
variation. For patients at initial stages of the disease, the overall one-year, two years and five years survival rates were 
73.2%, 52.8% and 31.2% respectively. For advanced stages, the survival ranged from 46.3% in the first year to 8.2% in 
the five years. The five-year survival rates (by year) were estimated to be 49%, 27%, 24%, 22% and 19% respectively. 
Conclusion: Tumor grade, tumor deferential, clinical staging and location of the tumor were the prognostic factors for 
survival in patients with esophageal cancer. 
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Introduction  
  1Esophageal cancer is the sixth cause of 
cancer death worldwide (1), with an estimated 
500,000 new cases each year (2). Esophageal 
cancer is a relatively common form of cancer in 
the eastern world (3). The disease is highly lethal, 
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with overall five-year survival rates less than 10%. 
The high mortality is due to the late onset of 
symptoms (4). Histologically, there are two main 
types; one type grows in the inside layer of the 
lining of the esophagus squamous cell carcinoma 
(SCC) a second cancer that starts in gland cells are 
called adenocarcinoma (AC) (5). 
A worldwide increasing incidence for AC but 
not for SCC has been reported in North America, 
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Europe and Japan (6). In Kerman province in Iran, 
an increased incidence of adenocarcinoma of the 
esophagus 1991 to 2002 has been reported while 
the incidence of esophageal SCC hardly increased. 
(7). In Ardabil province in 2007, the one- and 
five-years survival rates in patients with upper 
gastrointestinal cancer were estimated to be 40.5% 
and 0.8% respectively (8). Geographic variations 
in Iran show that the incidence and mortality of 
gastric cancer is higher in west and North West 
regions and in the Kurdistan province in 
particular. 
Previous survival studies in Iran have focused 
on esophageal cancer, indicating the importance of 
gender, age, residence (rural and urban) and risk 
factors whereas inconsistent results have been 
observed for education, and income (8-10). 
Factors such as histological type and grade, 
location and stage of tumor, surgical treatments 
have not been studied in relation to survival. 
Therefore, the present study aimed to investigate 
the effects of histological factors on the survival of 
patients with esophageal cancer.  
 
Patients and Methods 
Data were sourced mainly from the patient 
reports of pathology laboratories and hospital 
database record. Through a retrospective cohort 
study using censes method; all eligible patients 
with esophageal cancer (134 gastric cancers) who 
had been hospitalized at the Towhid hospital, 
Sanandaj city, Kurdistan province western Iran 
were recruited. Inclusion criteria were patients 
with definite diagnosis of esophageal cancer 
during a five-year period from 2006 onward. 
Samples were coded under the direct supervision 
of clinical pathologists according to the 
International Classification of Diseases for 
Oncology. Clinical data such as practice treatment 
were obtained through a structured questionnaire 
and the patients’ clinical records.  Vital status and 
date of death were determined through the by 
official death certificates, with a maximum 
follow-up of 90 months. Survival time (in months) 
was calculated from the date of diagnosis through 
the date of death or last follow-up. A failure was 
defined as death by any cause during the follow-
up period and patients alive at the end of the 
follow-up period were censored. 7 patients were 
excluded from the analyses according to exclusion 
criteria (4 patients lost follow-up, 2 illegible data, 
and 1 patient due to migration). Overall, 127 
patients with esophageal cancer were enrolled. 
Clinical and pathologic variables, which were sub-
layered into age, gender, setting, histological type 
of tumor and practice treatment were entered into 
parametric regression models (by considering and 
not considering heterogeneity) for multivariate 
analysis in order to assess the relationships 
between the characteristics and prognostic factors 
for survivors. Ilam University of Medical 
Sciences, Ethics Committee on considering of 
publication data result in general approved the 
study (Code No: 91002, Date: 22.08.2012). 
Statistical analysis 
The Kaplan Meier and Log rank statistic 
methods were used to compare survival rates in 
different subgroups. Using life table, survival rates 
and survival density function was assessed at year 
intervals. The Breslow (generalized Wilcoxon) 
statistics was used to compare median survival 
time in three age groups. The Cox hazards 
regression analysis was also used to investigate 
the effect of the variables and adjusting the effect 
of age. The graphical (diagram Log (S) t vs. time) 
and analytical (time-varying covariate) methods 
was applied to test the appropriateness of Cox’s 
proportional hazard (11).  
The Multivariate Cox regression analysis was 
used to identify independent predictors for patient 
survival using a backward stepwise approach with 
an entry limit of p<0.1 and a removal limit of 
p<0.05. The survival time of patients stratified by 
this grouping method were analyzed by the 
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Kaplan-Meier analysis and Cox regression as 
described earlier. All statistical analyses were 
performed using SPSS16.0.  
 
Results 
A total number of 127 patients (55.1% males) 
with esophageal cancer were recruited. Mean age 
±standard deviation was 65.38 ±11.62 years with a 
range of between 35 to 86 years. Based on 
histological type of tumor, 23 (18.1%) had AC 
type, 94 patients (74.0%) had SCC and other 
histological type 10 (7.9%). For 44 patients 
(36.6%), the tumors were located in the lower 
third of the esophagus. Meanwhile, the tumors 
were located in the middle third and upper third of 
the esophagus for 28 (22.0%) and 48 patients 
(37.8%) respectively. There were also overlapping 
lesions in 7 patients (5.5%). The tumors were well 
differentiated for 42 patients (48.8%), moderately 
differentiated for 35 patients (27.6%), poorly 
differentiated in 16 patients (12.6%) and unknown 
differentiated for 14 patients (11.0%).  
Gender and setting of patients had no 
significant effects on survival rate variation in 
univariate analysis. Age, location of tumor, 
histological type, tumor grade, stage of diagnosis 
and practice treatment showed a significant 
association on the survival rates variation (Table 
1). The Kaplan-Meier analysis revealed significant 
differences in five-year survival rate and age of 
diagnosis (log-rank=<0.001) (Figure1A), 
histological type (log-rank=0.004) (Figure1B), 
tumor grade (log-rank=0.017) (Figure1C), and 
tumor locate (log-rank=0.008) (Figure1D).     
Cox-regression analysis using histological 
factors 45> year as reference revealed that patients 
whose 46-65 year at diagnosis (HR= 3.43, 95% CI 
= 1.03-11.41, p= 0.044), 66< year (HR =9.78, 
95% CI = 2.93-32.64, p=< 0.001) had an increased 
risk for disease progression and death. Cox-
regression analysis for poor grade tumors as 
reference revealed that patients whose tumors with 
moderately differentiate (HR= 0.52, 95% CI = 
0.25-1.07, p= 0.078) and well differentiate (HR 
=0.98, 95% CI = 0.51-1.85, p= 0.951) had a 
decreased risk for death from esophageal cancer.  
 
Table 1. Clinic-pathological characteristic of the 
patients with esophageal cancer 
Factors Patients, n 
(%) 
Median of survival 
(CI 95%) 
Pvalue
Gender   0.480
 Male 70(55.1) 10(7.97-12.03)  
 Female 57(44.9) 12(6.46-17.54) 
Age   <0.001
 45> 11(8.7) 25(10.94-31.33)  
 46-65 54(42.5) 18(10.94-25.06) 
 66< 42(48.8) 6(4.6-7.4) 
Setting   0.148
 City 82(64.6) 10(8.05-11.95)  
 Village 45(35.4) 14(10.05-17.95) 
Histological type  <0.001
 AC 23(18.1) 7(4.18-9.82)  
 SCC 94(74.0) 13(9.34-16.66) 
Indeterminate 10(7.9) 10(7.93-12.07) 
Location of tumor  0.014
 Lower 44(34.6) 7(5.40-8.60)  
 Middle 28(22.0) 18(10.94-25.06) 
 Upper 48(37.8) 12(8.60-15.40) 
 Overlapping 
lesion 
7(5.5) 9(3.92-16.68) 
Histology grade   0.008
 Poorly 16(12.6) 7(1.12-12.88)  
 Moderately 35(27.6) 22(6.06-37.94) 
 Well 42(48.8) 9(6.80-11.20) 
 No Differential 14(11.0) 12(7.41-16.59) 
Stage   <0.001
 Localized 15(11.8) 25(12.02-35.98)  
 Regional 32(25.2) 24(13.01-34.99) 
 Distant 32(25.2) 10(6.32-13.68) 
 Unknown 38(37.08) 5(3.88-6.12) 
Practice treatment  <0.001
 surgery 15(11.8) 12(4.42-19.57)  
 chemotropic 30(23.6) 5(3.92-6.07) 
  radiotherapy 7(5.5) 5(2.91-7.09) 
 
Similar results were obtained for location of 
the tumor. Cox regression coefficient (β) analysis 
shows patient with tumor located in middle of 
esophaus (β=-0.91) and upper esophagus (β =-
0.13) have lower death rates compression to 
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tumors that are located in the lower esophagus. 
Similar results were obtained for tumor grade 
(Table 2F).  
Stage of tumor and practice treatment in step 2 
of Cox-regression analysis flowing demographic 
characteristic in step 1 using treatment surgery as 
reference revealed that patients who only had 
chemotherapy in process of treatment (HR=2.79, 
95% CI=1.35-5.73, p=0.005), and patients who 
only had radiotherapy (HR=7.27, 95% CI=1.53-
34.39, p=0.012) had an increased risk of deaths 
from esophageal cancer. Coefficient value β 
analysis shows patient who had only 
chemotherapy (β =1.98) have increase death rates 
in comparison to patients who had surgical 
operation only. Similar results were obtained for 
patient who only had chemotherapy (Table 2F).  
The five-year survival rates (by year) were 
49%, 27%, 24%, 22% and 19% respectively. 
Overall Five-year survival in the cases of 
esophageal cancer in the present study was 49.0%, 
with survival rates being higher in the group of 
women compared to the men (19.7% versus 
13.8%) (p = 0.48), higher in clinical localized 
stages (41.2%) compared to regional stages 
(14.3%) (p =< 0.001), one survival rate higher in 
cases submitted to curative surgery (53.2%) 
compared to those submitted to chemotherapy care 
(13.5), (p =< 0.001), as demonstrated in Table 3 
and Figure 2.  
 
Figure 1. The association between demographic, histological factors and survival in esophageal cancer patients. (A) 
By age of diagnosis (B) by histology of tumor (C) by histology grade (D) by location of tumor. 
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Table 2. Multivariate Cox regression analyses; F: Cox 
regression analysis for age, gender, setting, stage at 
diagnosis and practice treatment; E: Cox-regression 
analysis for age, gender, setting, histology grade and 
location of tumor 
F    Characteristics β HR(95% 
CI) 
P-
value 
Age - Overall <0.001 
45 (n=10) Ref 1 Ref 
46-65(n=54) 0.628 1.87(0.56-
6.24) 
0.307 
65(n=63) 1.59 4.92(1.46-
16.53) 
0.010 
Practice treatment - Overall <0.001 
Surgery(n=15) Ref 1 Ref 
Chemotherapy(n=30) 1.02 2.79(1.35-
5.73) 
0.005 
Radiotherapy(n=2) 1.98 7.27(1.53-
34.39) 
0.012 
surgery and 
chemotherapy(n=19) 
-0.74 0.47(0.19-
1.12) 
0.089 
chemotherapy and 
radiotherapy(n=15) 
-.60 0.54(0.21-
1.37) 
0.199 
surgery, chemotherapy 
and radiotherapy(n=16) 
-1.01 0.36(0.13-
0.95) 
0.040 
no treatment(n=30) 1.12 3.08(1.50-
6.34) 
0.002 
 
Figure2. Cumulative survival rate in patients with 
esophageal cancer 
 
Discussion 
In a recent review of survival analyses, it was 
found that many studies have indicated clinical 
and pathologic characteristics of patients as 
explanatory variables with respect to survival (12). 
Age of diagnosis was an independent covariate for 
survival in patients in this study and better 
prognosis observed in >45 year age group. The 
reasons for this are likely to include a combination 
of better general health, more effective response to 
treatment and earlier diagnosis in younger people. 
Differences in underlying tumor biology may also 
play a part. Previous report indicated better 
survival in young patients (13). On the other hand, 
some other studies do not have the same report 
(14, 15). The present results showed that patients' 
gender had no significant impact on survival rate 
(p=0.48). Median survival time for man and women 
was (10.0±1.03) and (12.0±2.83), respectively. Sex 
was not an independent prognostic factor in either 
Chinese patients (p=0.23) or white patients living in 
the United States (p=0.28). Overall survival was 
significantly worse only in male white compared 
with Chinese patients (median survival time, 12.4 
versus 14.5 months, respectively; p<0.01), (8). 
However, some studies have found better survival 
rate for women (10). 
E Characteristics β HR  
(95% CI) 
P-value
Age - Overall <0.001
45> Ref 1 Ref 
46-65 1.23 3.43 
(1.03-11.41) 
0.044 
<65 2.28 9.78 
(2.93-32.64) 
<0.001
Histology grade - Overall 0.085 
poorly Ref 1 Ref 
Moderately -0.64 0.52 
(0.25-1.07) 
0.078 
well -0.02 0.98 
(0.51-1.85) 
0.951 
Location of tumor - Overall 0.009 
Lower Ref 1 Ref 
Middle -0.91 0.40 
(0.22-0.73) 
0.003 
Upper -0.13 0.53 
(0.33-0.85) 
0.009 
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Table 3. The 1-5 year survival rates and med time 
survival in patients with esophageal cancer 
Survival variables Survival rates (%) Med time
Survival
by month
1year 2year 3year 4year 5year
Gender     
Male 46.1 26.3 19.1 19.3 13.8 11.7
Female 52.8 29.6 24.5 18.2 19.7 13.4
Age     
45> 80.2 80.1 68.5 68.3 68.3 60 
46-65 72.1 38.8 31.3 27.8 27.2 20.2
66< 24.8 8.3 4.2 4.3 - 7.9 
Histological type   
AC 21.3 19.7 5.1 1.3 - 7.6 
SCC 56.3 32.8 25.3 22.8 19.6 15.3
Location of tumor    
 Lower 34.5 28.3 23.7 15.1 15.3 9.3 
 Middle 64.2 44.2 31.8 25.3 21.7 22.3
 Upper 54.3 34.9 29.2 28.4 24.2 14.2
Histology grade    
 Poorly 31.3 28.7 18.3 18.9 16.3 9.6 
 Moderately 74.2 47.6 39.7 33.8 25.3 23.13
 Well 37.6 17.5 13.5 11.7 11.2 9.5 
Stage      
 Localized 73.2 52.8 45.3 45.6 31.2 30 
 Regional 62.5 27.3 2.03 20.5 14.3 26 
 Distant 46.3 24.6 24.02 12.5 8.2 11.3
Practice treatment    
 Surgery 53.2 30.6 21.3 21.3 - 13.9
 Chemotropic 13.5 - - - - 6.9 
 
 The SCC cancer is a significant factor that had 
impact on the survival probability of patients in 
univariate analysis, which is similar to some other 
studies. This result reinforced SCC and AC are 
distinct malignancies of the esophagus, with 
different risk factors and different natural 
histories. In this study patient with SCC histology 
had a better survival, although in previous studies 
ACs generally have a slightly better prognosis 
(outlook) in overall(12).  
Stage of diagnosis was strongly associated with 
prognosis in our study, which is a finding repeated 
in several other studies (4, 10). Overall, the five-
year survival rate of people with esophageal 
cancer is about 17%. However, survival rates 
depend on several factors, including the stage (or 
extent) of the cancer at the time of diagnosis. 
Fortunately, new treatment approaches have 
lowered the death rate from esophagus cancer, 
which at one time killed 95% of those diagnosed 
with the disease. Today, about 16% of all 
esophageal cancer patients will survive five years 
or more (13).  As with most types of cancer, 
survival odds increase when the disease is caught 
and treated early (16). The five-year survival rate 
of people with cancer located only in the 
esophagus is about 41.2%. The five-year rate for 
those with disease that has spread regionally is 
14.3%, if it has spread to distant organs, about 
8.2% (Table2).  
Surgical results in treatment of esophageal 
cancer have improved significantly over recent 
years. However, medical centers now report that 
patients undergoing surgery alone have median 
survival rates between 13 and 19 months, 2-year 
survival rates between 35% and 42%, and 5-year 
survival rates of 15% to 24% (17). In present 
study median of survival and 4-year survival rate 
in this cases was (12±3.86 month) and (21.3), 
respectively. In patients that radiation therapy was 
the only optionfor treatment the mean survival rate 
was (5 ±1.06 month). Radiation therapy has been 
used in the past as a single-modality approach 
with curative intent. However, except for those 
with very early-stage disease, radiation has had 
little impact on long-term survival. Chemotherapy 
has been given preoperatively, postoperatively, or 
both median survival rates were (5±0.548 month). 
Multimodality treatment approaches have evolved 
over recent years in response to the frequent loco 
regional and distant recurrences identified after 
surgery or radiation therapy alone.  
There are limitations with the present study in 
which the survival rate unable to predict future 
events for a particular person. Meanwhile, it was 
not possible to consider changes in characteristics 
after diagnosis, which may have affected survival. 
Hospital series often provide more optimistic data. 
They are of limited value because of unavoidable 
 Veisani Y. et al  107 
Gastroenterol Hepatol Bed Bench 2014;7(2):101-107 
selection bias, in particular in case selection and 
patient's characteristics. 
In conclusions, the present study showed that 
age of diagnosis, histological grade, and location 
of tumor was prognostic factors for survival in 
patients with esophageal cancer. It can be 
concluded the early detection of patients at 
younger age and in primary stages and histological 
grade may have positive effect on patients with 
esophageal cancer and be important to increase the 
survival time. 
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